Vistin Pharma ASA Market Cap ($85.86 Million)
Market Cap & Net Worth: Vistin Pharma ASA (VISTN)
Vistin Pharma ASA market cap. Vistin Pharma ASA (OL:VISTN) has a market capitalization of $85.86 Million (Nkr815.94 Million) as of October 31, 2026. Listed on the OL stock exchange, this Norway-based company holds position #19584 globally and #175 in its home market, demonstrating a 1.66% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vistin Pharma ASA's stock price Nkr18.40 by its total outstanding shares 44344592 (44.34 Million).
Vistin Pharma ASA Market Cap History (2015–2026)
Vistin Pharma ASA market cap history from 2015 to 2026. Data shows growth from $75.75 Million to $85.86 Million (3.00% CAGR). Check VISTN share price today for real-time trading data and today's change.
Vistin Pharma ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vistin Pharma ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see cash flow conversion of Vistin Pharma ASA for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.21x
Vistin Pharma ASA's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.30x
Vistin Pharma ASA's market cap is 1.30 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $87.45 Million | $170.51 Million | $12.92 Million | 0.51x | 6.77x |
| 2017 | $49.29 Million | $176.69 Million | $70.40 Million | 0.28x | 0.70x |
| 2018 | $29.13 Million | $198.99 Million | -$73.63 Million | 0.15x | N/A |
| 2019 | $40.61 Million | $227.19 Million | $66.20 Million | 0.18x | 0.61x |
| 2020 | $73.96 Million | $253.16 Million | -$96.95 Million | 0.29x | N/A |
| 2021 | $83.93 Million | $278.62 Million | $24.95 Million | 0.30x | 3.36x |
| 2022 | $68.43 Million | $287.68 Million | -$4.72 Million | 0.24x | N/A |
| 2023 | $100.91 Million | $435.39 Million | $45.60 Million | 0.23x | 2.21x |
| 2024 | $110.59 Million | $429.09 Million | $62.75 Million | 0.26x | 1.76x |
| 2025 | $97.06 Million | $452.29 Million | $74.75 Million | 0.21x | 1.30x |
Competitor Companies of VISTN by Market Capitalization
Companies near Vistin Pharma ASA in the global market cap rankings as of October 31, 2026. See VISTN equity financing ratio to understand what proportion of total assets are financed by equity.
Key companies related to Vistin Pharma ASA by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Vistin Pharma ASA (2015–2026)
Market capitalization of Vistin Pharma ASA from 2015 to today. Between 2015 and today, Vistin Pharma ASA's market cap moved from $75.75 Million to $ 85.86 Million, with a yearly change of 3.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr85.86 Million | -11.54% |
| 2025 | Nkr97.06 Million | -12.24% |
| 2024 | Nkr110.59 Million | +9.59% |
| 2023 | Nkr100.91 Million | +47.47% |
| 2022 | Nkr68.43 Million | -18.47% |
| 2021 | Nkr83.93 Million | +13.48% |
| 2020 | Nkr73.96 Million | +82.13% |
| 2019 | Nkr40.61 Million | +39.41% |
| 2018 | Nkr29.13 Million | -40.91% |
| 2017 | Nkr49.29 Million | -43.63% |
| 2016 | Nkr87.45 Million | +15.43% |
| 2015 | Nkr75.75 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Vistin Pharma ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.86 Million USD |
| MoneyControl | $85.86 Million USD |
| MarketWatch | $85.86 Million USD |
| marketcap.company | $85.86 Million USD |
| Reuters | $85.86 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) in Africa, Europe, Asia, and North and South America. It offers metformin HCl; metformin direct compressible; and metformin premixed with lubricant magnesium stearate for use in plain metformin immediate release tablets. The company was founded in 1969 and is… Read more